People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Jim Cramer in a latest program on CNBC discussed the reasons behind the recent market declines after the ISM Services Index ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

People using weed for medical purposes are as likely -- or more -- to become addicted to cannabis as recreational tokers, a ...

As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

J&J’s 2025 results will be the launching point for its guidance of 5%-7% revenue growth for 2025-30, which is still well ...

WASHINGTON – House Republicans gave Mike Johnson the speaker's gavel on Friday – along with a warning. Nine GOP lawmakers at first either abstained from voting for Johnson or voted for a ...